No Data
Catalyst Watch: Netflix Earnings, Monster Beverage Event, Drug Data, and Quantum Volatility
Jasper Therapeutics Price Target Cut to $40.00/Share From $60.00 by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $40
Jasper Therapeutics Is Maintained at Outperform by RBC Capital
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $40 to $80
RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk